Table 1 Characteristics of the subjects according to MAFLD
From: Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Total subjects (n = 852) | MAFLD | p-value | AUROC (95% CI) | |
|---|---|---|---|---|
No (n = 574) | Yes (n = 278) | |||
Sex | < 0.0001 | |||
Male | 300 (52.3) | 209 (75.2) | ||
Female | 274 (47.7) | 69 (24.8) | ||
Alcohol consumption | 0.147 | |||
N | 360 (62.7) | 160 (57.6) | ||
Y | 214 (37.3) | 118 (42.4) | ||
Smoking | < 0.0001 | |||
N | 446 (77.7) | 184 (66.2) | ||
Y | 128 (22.3) | 94 (33.8) | ||
FLI | < 0.0001 | |||
30 < | 407 (89.8) | 80 (43.0) | ||
≥ 60 | 46 (10.2) | 106 (57.0) | ||
Age (years) | 52.44 ± 10.20 | 52.97 ± 9.31 | 0.462 | |
BMI | 23.63 ± 2.84 | 26.64 ± 3.12 | < 0.0001 | |
SBP (mmHg) | 121.19 ± 12.59 | 126.15 ± 11.77 | < 0.0001 | |
DBP (mmHg) | 74.63 ± 9.56 | 78.84 ± 10.02 | < 0.0001 | |
WC (cm) | 82.34 ± 8.07 | 89.23 ± 9.17 | < 0.0001 | |
FBS (mg/dL) | 92.3 ± 23.38 | 99.93 ± 26.27 | < 0.0001 | |
TG (mg/dL) | 98.8 ± 64.16 | 150.91 ± 143.04 | < 0.0001 | |
HDL-C (mg/dL) | 56.74 ± 12.9 | 52.4 ± 13.72 | < 0.0001 | |
LDL-C (mg/dL) | 119.53 ± 32.72 | 124.16 ± 38.03 | 0.082 | |
AST (IU/L) | 30.82 ± 21.94 | 37.66 ± 38.42 | 0.001 | |
ALT (IU/L) | 27.52 ± 24.32 | 40.15 ± 29.71 | < 0.0001 | 0.701 (0.657–0.745) |
GGT (IU/L) | 36.76 ± 66.86 | 72.79 ± 215.35 | 0.007 | 0.668 (0.622–0.714) |
Uric acid/creatinine | 6.29 ± 1.75 | 6.61 ± 1.56 | 0.011 | |
hs-CRP (mg/L) | 1.65 ± 3.93 | 2.03 ± 3.61 | 0.216 | 0.620 (0.572–0.668) |
TC (mg/dL) | 199.95 ± 35.45 | 205.11 ± 44.30 | 0.091 | |
WBC (103/µL) | 6019.63 ± 1735.57 | 6722.82 ± 1950.21 | < 0.0001 | |
Hemoglobin (g/dL) | 14.23 ± 1.50 | 15.34 ± 1.50 | < 0.0001 | 0.682 (0.635–0.729) |
Insulin (µIU/mL) | 4.41 ± 3.02 | 7.76 ± 6.46 | < 0.0001 | 0.717 (0.672–0.761) |
Vitamin D (ng/mL) | 18.99 ± 8.89 | 19.27 ± 7.86 | 0.688 | |
Fatty liver index | 23.1 ± 20.75 | 48.63 ± 25.5 | < 0.0001 | 0.776 (0.737–0.816) |